homepage-top-section

City of Hope will assess the investigational vaccine, dubbed COH04S1, in healthy volunteers aged between 18 and 55 who have not had Covid-19. The investigational vaccine is being

Deucravacitinib, a novel, oral and selective tyrosine kinase 2 (TYK2) inhibitor, is being assessed in clinical studies across multiple immune-mediated diseases such as psoriasis, psoriatic arthritis, lupus and

Aurinia has also secured funding for the VOCOVID study, which is a single-centre and investigator-initiated trial being carried out by Drs Aiko P.J. de Vries and Y.K. Onno

The trial’s top-line data from 203 participants demonstrate that severe or critical Covid-19 patients treated with SACCOVID witnessed speedy recovery and a significant reduction in disease progression to

The deal also allows Inflazome to secure additional contingent payments based on the achievement of certain predetermined milestones. Based in Dublin, Inflazome is engaged in the development of

The vaccine candidate is being developed using Sanofi’s recombinant protein-based technology and GSK’s advanced adjuvant technology. Sanofi’s protein-based technology is currently used to produce an influenza vaccine. Both

Situated at the company’s R&D headquarters in Boston, the new facility offers end-to-end research and development services to advance the development of next-generation cell therapies. The new R&D

Merck and Seattle Genetics have entered into two strategic oncology collaborations to commercialise Seattle Genetics’ antibody-drug conjugate (ADC) ladiratuzumab vedotin and small-molecule tyrosine kinase inhibitor (TKI) Tukysa (tucatinib).

Ibrutinib, a once-a-day drug that is administered orally, inhibits the first-in-class Bruton’s tyrosine kinase (BTK) that sends crucial signals to B cells to mature and produce antibodies, said